Stereotaxis Stock Declines as Q3 Loss Increases, GenesisX Limited Launch in Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Should l Buy STXS?
Source: SeekingAlpha
Company Performance: Stereotaxis (STXS) shares dropped 12% after reporting a wider loss and a 19% revenue decline, missing analyst expectations.
Future Revenue Expectations: The company anticipates fourth-quarter revenue exceeding $9 million, driven by system and recurring revenues, particularly from its new catheter portfolio.
Product Launch and Development: Stereotaxis is initiating a limited launch of the GenesisX system while awaiting approval for the MAGiC catheter, which aims to enhance compatibility and improve manufacturing processes.
Growth Potential: The CEO highlighted that the introduction of robotically steered catheters is expected to significantly boost recurring revenue, with early success from the MAGiC Sweep catheter generating over $300,000 in revenue within the first two months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STXS
Wall Street analysts forecast STXS stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.820
Low
4.00
Averages
4.20
High
5.00
Current: 1.820
Low
4.00
Averages
4.20
High
5.00
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DAFNA Capital Management Reduces Stake in Biotechnology ETF
- Share Reduction: DAFNA Capital Management sold 34,405 shares of iShares Biotechnology ETF (IBB) in Q4 2025, resulting in a $3.31 million decrease in quarter-end position value, reflecting both trading activities and stock price fluctuations.
- Asset Management Impact: This transaction reduced IBB's share of DAFNA's 13F reportable assets to 2.67%, indicating that IBB is no longer among the fund's top five holdings, which highlights its diminishing significance in the investment portfolio.
- Market Performance: As of February 17, 2026, IBB's price stood at $174.02, marking a 27.2% increase over the past year, with an alpha of 15.84 percentage points compared to the S&P 500, showcasing the ETF's strong performance in the biotechnology sector.
- Investment Strategy: The iShares Biotechnology ETF primarily invests in large, commercial-stage biotech companies and employs a passive investment strategy aimed at efficient index replication and liquidity management, although it remains sensitive to interest rates and investor risk appetite.
See More
DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF
- Stake Reduction Details: According to an SEC filing dated February 17, 2026, DAFNA Capital Management reduced its stake in the iShares Biotechnology ETF by 34,405 shares during Q4 2025, resulting in a $3.31 million decrease in position value, highlighting the impact of market fluctuations on the portfolio.
- Asset Allocation Shift: Following the sale, the iShares Biotechnology ETF now comprises 2.67% of DAFNA Capital's 13F reportable assets, indicating a relative decline in the ETF's significance within the overall investment strategy.
- Top Holdings Overview: As of February 17, 2026, DAFNA's top five holdings include NASDAQ:RVMD at $48.15 million (11.3% of AUM) and NYSEMKT:XBI at $41.03 million (9.7% of AUM), reflecting a continued focus on large-cap biotech firms in its investment approach.
- ETF Performance Analysis: As of February 17, 2026, the iShares Biotechnology ETF was priced at $174.02, up 27.2% over the past year, demonstrating stable performance in the biotech sector, though it remains sensitive to shifts in market risk appetite for growth-oriented healthcare stocks.
See More
Stereotaxis Reports 36% Revenue Growth in Q4
- Significant Revenue Growth: Stereotaxis Inc (STXS) reported fourth-quarter revenue of $8.6 million, a 36% increase from $6.3 million in the prior year, reflecting strong performance in system and catheter sales, which enhances the company's competitive position in the medical device market.
- Product Portfolio Expansion: The company plans to launch MAGiC with Pulse Field Ablation in Europe by year-end, aiming to boost revenue potential through new product marketing, although the commercial contribution from new products remained modest in 2025.
- Operational Cost Challenges: Operating expenses for Q4 reached $10 million, including $3 million in non-cash charges, and while adjusted operating expenses were $7 million, high operational costs continue to pressure financial results, impacting the company's profitability.
- Cash Flow Position: As of the end of 2025, Stereotaxis had cash and cash equivalents of $13.4 million, facing a negative free cash flow of $13.8 million; however, the company's debt-free status provides a safeguard for future growth.
See More
Stereotaxis Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Q4 2025 revenue reached $8.6 million, a 36% increase year-over-year, reflecting substantial progress in catheter sales, with annual revenue projected to exceed $40 million in 2026, indicating strong market demand and growth potential.
- Technological Advancements and Regulatory Milestones: The company achieved regulatory approvals for the GenesisX robot and MAGiC catheters in the U.S. and Europe, underscoring its leadership in minimally invasive surgery technology, which is expected to drive future sales and market share growth.
- Commercial Model Transformation: Stereotaxis is shifting from large capital sales to a model based on sales, leases, and placements funded by disposable commitments, increasing revenue per procedure from $1,000 to over $5,000, enhancing revenue diversity and sustainability.
- Manufacturing Capacity Expansion Plans: The company anticipates producing one GenesisX robot every two months in 2026 and ramping MAGiC catheter production from 100 to 500 units per month in partnership with Osypka, aiming to meet growing market demand and overcome manufacturing bottlenecks.
See More
Stereotaxis Q4 Earnings Report Analysis
- Earnings Performance: Stereotaxis reported a Q4 GAAP EPS of -$0.06, beating expectations by $0.01, indicating a slight improvement in profitability despite remaining in the red.
- Revenue Growth: The company's Q4 revenue reached $8.64 million, reflecting a 36.3% year-over-year increase, although it fell short of market expectations by $0.6 million, suggesting room for improvement in market demand.
- Market Reaction Analysis: Despite missing revenue expectations, the earnings beat may positively influence investor sentiment, potentially increasing stock price volatility in the short term, reflecting market interest in the company's future potential.
- Historical Financial Data Comparison: Analyzing historical financial data, Stereotaxis shows a revenue growth trend that highlights its competitive position in the medical device sector, with prospects for achieving higher revenue levels through ongoing innovation and market expansion.
See More
Stereotaxis to Announce Q4 Earnings on March 9th
- Earnings Announcement Date: Stereotaxis is set to release its Q4 earnings on March 9th after market close, with investors keenly awaiting the results to gauge the company's future growth potential.
- Earnings Estimate Analysis: The consensus EPS estimate stands at -$0.07, reflecting a 22.2% year-over-year increase, indicating the company's efforts to improve profitability despite still being in the negative.
- Revenue Growth Expectations: The consensus revenue estimate is $9.24 million, representing a 45.7% year-over-year increase, showcasing strong sales momentum amid rising market demand.
- Historical Performance Review: Over the past year, Stereotaxis has beaten EPS estimates 0% of the time and revenue estimates 25% of the time, highlighting challenges in meeting profitability expectations.
See More
DAFNA Capital Management Reduces Stake in Biotechnology ETF
- Share Reduction: DAFNA Capital Management sold 34,405 shares of iShares Biotechnology ETF (IBB) in Q4 2025, resulting in a $3.31 million decrease in quarter-end position value, reflecting both trading activities and stock price fluctuations.
- Asset Management Impact: This transaction reduced IBB's share of DAFNA's 13F reportable assets to 2.67%, indicating that IBB is no longer among the fund's top five holdings, which highlights its diminishing significance in the investment portfolio.
- Market Performance: As of February 17, 2026, IBB's price stood at $174.02, marking a 27.2% increase over the past year, with an alpha of 15.84 percentage points compared to the S&P 500, showcasing the ETF's strong performance in the biotechnology sector.
- Investment Strategy: The iShares Biotechnology ETF primarily invests in large, commercial-stage biotech companies and employs a passive investment strategy aimed at efficient index replication and liquidity management, although it remains sensitive to interest rates and investor risk appetite.
See More
DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF
- Stake Reduction Details: According to an SEC filing dated February 17, 2026, DAFNA Capital Management reduced its stake in the iShares Biotechnology ETF by 34,405 shares during Q4 2025, resulting in a $3.31 million decrease in position value, highlighting the impact of market fluctuations on the portfolio.
- Asset Allocation Shift: Following the sale, the iShares Biotechnology ETF now comprises 2.67% of DAFNA Capital's 13F reportable assets, indicating a relative decline in the ETF's significance within the overall investment strategy.
- Top Holdings Overview: As of February 17, 2026, DAFNA's top five holdings include NASDAQ:RVMD at $48.15 million (11.3% of AUM) and NYSEMKT:XBI at $41.03 million (9.7% of AUM), reflecting a continued focus on large-cap biotech firms in its investment approach.
- ETF Performance Analysis: As of February 17, 2026, the iShares Biotechnology ETF was priced at $174.02, up 27.2% over the past year, demonstrating stable performance in the biotech sector, though it remains sensitive to shifts in market risk appetite for growth-oriented healthcare stocks.
See More
Stereotaxis Reports 36% Revenue Growth in Q4
- Significant Revenue Growth: Stereotaxis Inc (STXS) reported fourth-quarter revenue of $8.6 million, a 36% increase from $6.3 million in the prior year, reflecting strong performance in system and catheter sales, which enhances the company's competitive position in the medical device market.
- Product Portfolio Expansion: The company plans to launch MAGiC with Pulse Field Ablation in Europe by year-end, aiming to boost revenue potential through new product marketing, although the commercial contribution from new products remained modest in 2025.
- Operational Cost Challenges: Operating expenses for Q4 reached $10 million, including $3 million in non-cash charges, and while adjusted operating expenses were $7 million, high operational costs continue to pressure financial results, impacting the company's profitability.
- Cash Flow Position: As of the end of 2025, Stereotaxis had cash and cash equivalents of $13.4 million, facing a negative free cash flow of $13.8 million; however, the company's debt-free status provides a safeguard for future growth.
See More
Stereotaxis Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Q4 2025 revenue reached $8.6 million, a 36% increase year-over-year, reflecting substantial progress in catheter sales, with annual revenue projected to exceed $40 million in 2026, indicating strong market demand and growth potential.
- Technological Advancements and Regulatory Milestones: The company achieved regulatory approvals for the GenesisX robot and MAGiC catheters in the U.S. and Europe, underscoring its leadership in minimally invasive surgery technology, which is expected to drive future sales and market share growth.
- Commercial Model Transformation: Stereotaxis is shifting from large capital sales to a model based on sales, leases, and placements funded by disposable commitments, increasing revenue per procedure from $1,000 to over $5,000, enhancing revenue diversity and sustainability.
- Manufacturing Capacity Expansion Plans: The company anticipates producing one GenesisX robot every two months in 2026 and ramping MAGiC catheter production from 100 to 500 units per month in partnership with Osypka, aiming to meet growing market demand and overcome manufacturing bottlenecks.
See More
Stereotaxis Q4 Earnings Report Analysis
- Earnings Performance: Stereotaxis reported a Q4 GAAP EPS of -$0.06, beating expectations by $0.01, indicating a slight improvement in profitability despite remaining in the red.
- Revenue Growth: The company's Q4 revenue reached $8.64 million, reflecting a 36.3% year-over-year increase, although it fell short of market expectations by $0.6 million, suggesting room for improvement in market demand.
- Market Reaction Analysis: Despite missing revenue expectations, the earnings beat may positively influence investor sentiment, potentially increasing stock price volatility in the short term, reflecting market interest in the company's future potential.
- Historical Financial Data Comparison: Analyzing historical financial data, Stereotaxis shows a revenue growth trend that highlights its competitive position in the medical device sector, with prospects for achieving higher revenue levels through ongoing innovation and market expansion.
See More
Stereotaxis to Announce Q4 Earnings on March 9th
- Earnings Announcement Date: Stereotaxis is set to release its Q4 earnings on March 9th after market close, with investors keenly awaiting the results to gauge the company's future growth potential.
- Earnings Estimate Analysis: The consensus EPS estimate stands at -$0.07, reflecting a 22.2% year-over-year increase, indicating the company's efforts to improve profitability despite still being in the negative.
- Revenue Growth Expectations: The consensus revenue estimate is $9.24 million, representing a 45.7% year-over-year increase, showcasing strong sales momentum amid rising market demand.
- Historical Performance Review: Over the past year, Stereotaxis has beaten EPS estimates 0% of the time and revenue estimates 25% of the time, highlighting challenges in meeting profitability expectations.
See More
